Literature DB >> 17904958

Risk assessment to guide the prevention of cervical cancer.

Philip E Castle1, Mario Sideri, Jose Jeronimo, Diane Solomon, Mark Schiffman.   

Abstract

Advances in screening and diagnosis make it increasingly possible to prevent cervical cancer. However, if misused or poorly understood, these new tools will only increase costs and potentially harm patients without benefit. As a framework for standardized care that maximizes patient safety and well-being, we propose that a risk model be adopted to guide clinical management now and in the future. The model would use thresholds of increasing risk for cervical precancer and treatable cancer to guide clinical decision making for screening intensity, diagnostic evaluation, or treatment. Experts would decide on these risk thresholds and stratum based on the patient risk to benefit, independent of current (eg, cytology, carcinogenic HPV testing, and colposcopy) and future methods of measuring risk. A risk management model for cervical cancer prevention, based on appropriate clinical actions that correspond to risk stratum, can result in better allocation of resources to and increased safety for women at the greatest risk and increased well-being for women at the lowest risk.

Entities:  

Mesh:

Year:  2007        PMID: 17904958      PMCID: PMC2128712          DOI: 10.1016/j.ajog.2007.07.049

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  46 in total

Review 1.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

Review 2.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

3.  Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples.

Authors:  Yi-Shan Yang; Karen Smith-McCune; Teresa M Darragh; Yvonne Lai; Ju-Hwa Lin; Ting-Chang Chang; Hsiao-Yun Guo; Tiea Kesler; Alicia Carter; Philip E Castle; Shuling Cheng
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

4.  Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24.

Authors:  Gaea Moore; Barbara Fetterman; J Thomas Cox; Nancy Poitras; Thomas Lorey; Walter Kinney; Philip E Castle
Journal:  J Low Genit Tract Dis       Date:  2010-04       Impact factor: 1.925

5.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

Review 6.  Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer.

Authors:  Lan Xu; Freija Verdoodt; Nicolas Wentzensen; Christine Bergeron; Marc Arbyn
Journal:  Cancer Cytopathol       Date:  2015-11-30       Impact factor: 5.284

7.  Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma.

Authors:  Feng Ye; Yan Yu; Yuting Hu; Weiguo Lu; Xing Xie
Journal:  J Exp Clin Cancer Res       Date:  2010-06-18

8.  Risk estimation for the next generation of prevention programmes for cervical cancer.

Authors:  Hormuzd A Katki; Sholom Wacholder; Diane Solomon; Philip E Castle; Mark Schiffman
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

9.  Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities.

Authors:  Julia C Gage; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Philip E Castle; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-19       Impact factor: 4.254

Review 10.  Human papillomavirus infection and the primary and secondary prevention of cervical cancer.

Authors:  Douglas R Lowy; Diane Solomon; Allan Hildesheim; John T Schiller; Mark Schiffman
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.